Dealbreaker on MSN11h
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.
FiercePharma3d
Once valued at $10B, bluebird bio sold to private equity firms for $29M
That’s what Carlyle and SK Capital are paying for the 15-year-old Massachusetts biotech in a deal that was announced on Friday. There is a catch. If the private equity firms can boost sales of ...
Benzinga.com3d
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
Bluebird bio to be acquired by Carlyle Group & SK Capital, offering up to $9.84/share based on product performance. Former Mirati CEO David Meek set to lead bluebird post-acquisition, with deal ...
The Boston Globe3d
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the beleaguered ...